Adaptive Biotechnologies Corporation (ADPT) - Stock Analysis
Last updated: Jun 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Adaptive Biotechnologies (ADPT) exhibits strong short-term momentum with a recent earnings beat, 52% YoY MRD revenue growth, raised guidance, and technical breakout above the upper Bollinger Band, complemented by favorable biotech sector tailwinds.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Gross Margin ⢠Cash Burn ⢠Cost Pressure ADPT has strong 74% gross margins and adequate liquidity, but persistent losses, rising operating costs, negative cash flow, and a rich valuation show the business is not yet converting revenue into profitability.
Price Behavior
Key Price Behavior Insights: ⢠Higher highs ⢠Breakout support ⢠Profit taking Support Level: $16.70-$17.00 Resistance Level: $18.73 ADPT has posted a strong short-term uptrend with a breakout above mid-$15 and a last-month high, but the recent pullback suggests it is stretched and must hold $16.70-$17.00 to keep momentum intact.
Sentiment & News
Key News Insights: ⢠MRD Adoption ⢠Conference Outreach ⢠Estimate Revisions Adaptive Biotechnologies continues to build momentum in its clonoSEQ/MRD franchise with supportive ASCO/EHA data, active investor outreach, and a recent stock pop on improved earnings revisions despite some insider selling.
AI Summary
ADPT is transitioning from a platform story to a real commercial execution story driven by clonoSEQ/MRD adoption, but the investment case now hinges on proving operating leverage because revenue growth is still being offset by widening losses, cash burn, and a rich valuation, even as the stock's technical momentum remains constructive.
Description
Adaptive Biotechnologies is a commercial-stage company that develops immune-based diagnostics and therapeutics, offering sequencing and clinical assays to detect and monitor cancer, infectious diseases and immune-related conditions. Its portfolio includes research and clinical immunosequencing products and laboratory diagnostics for minimal residual disease and past infection detection, and it supports life-science research, clinical diagnostics and drug discovery. The company maintains strategic collaborations with Genentech on neoantigen-directed T-cell therapies and with Microsoft on computational diagnostic efforts; it was incorporated in 2009 and is headquartered in Seattle, Washington.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Nov 25 | Dec 2 | ADPT | Adaptive Biotechnologies Corporation | Adaptive Biotechnologies (ADPT) exhibits strong short-term momentum with a recent earnings beat, 52% YoY MRD revenue growth, raised guidance, and technical breakout above the upper Bollinger Band, complemented by favorable biotech sector tailwinds. | Closed | -8.0% |